CTMC Welcomes New Executive Team Members
CTMC, a pioneering joint venture focused on advancing cell therapies, has exciting news. The company has appointed Amy Hay as Chief Business Officer and Duane Avant as Chief Technical Officer. These key appointments mark a significant step in CTMC’s ambition to enhance its cell therapy support initiatives.
Strengthening Commitment to Cell Therapy
Jason Bock, the CEO of CTMC, stated, “The addition of these two executives represents our ongoing commitment to accelerate impactful cell therapies reaching patients.” He expressed enthusiasm about welcoming Amy and Duane into the CTMC family. “With Amy’s extensive background in building strategic alliances and Duane’s expertise in operational execution, we’re set to further our partners’ successes and the success of our innovative therapies,” he added.
Amy Hay's Vision and Experience
Amy Hay joins CTMC with a robust portfolio of experience, previously serving as Senior Vice President of Strategy and Business Development at Varian, a Siemens Healthineers company with an impressive annual revenue. In her new role, she focuses on market exploration, strategic partnerships, and revenue growth underpinning CTMC’s long-term vision.
Background and Achievements
Amy’s past roles include leadership positions at The University of Texas MD Anderson Cancer Center, where she helped shape regional strategies for cancer care. With a BA degree in psychology and a master's in healthcare administration, her educational background complements her professional experience.
Duane Avant's Expertise in Operations
With over 25 years in the biopharma industry, Duane Avant seizes the Chief Technical Officer role to bolster CTMC’s operational framework. He is passionate about the prospects offered by CTMC’s innovative approach to therapy development and manufacturing.
Commitment to Quality and Efficiency
As Chief Technical Officer, Duane is well-positioned to enhance CTMC’s operational standards, with a focus on ensuring quality while expediting the manufacturing process. His history in achieving significant milestones, including multiple IND submissions since CTMC’s inception, underscores his capabilities.
Cumulative Experience and Impact
Throughout his career, Duane has driven forward the quality assurance processes within the field of cell and gene therapy. His record speaks volumes about his ability to streamline operations while adhering to regulatory standards. He is a Lean Six Sigma Black Belt, illustrating his commitment to continuous improvement.
About CTMC
CTMC stands at the forefront of cell therapy innovation. As a collaboration between Resilience and MD Anderson Cancer Center, CTMC aims to expedite impactful therapies for cancer patients. Leveraging its strategic location within a leading medical center and expertise in therapy development, CTMC is poised to lead clinical trials faster and pave the way for robust commercialization.
Frequently Asked Questions
What positions have been added to CTMC’s leadership team?
CTMC has appointed Amy Hay as Chief Business Officer and Duane Avant as Chief Technical Officer to strengthen its leadership team.
What is the primary focus of Amy Hay in her new role?
Amy Hay will focus on developing business strategies that enhance market penetration, foster partnerships, and drive revenue growth at CTMC.
How many years of experience does Duane Avant bring to his role?
Duane Avant brings over 25 years of experience in the biopharma industry to his position as Chief Technical Officer at CTMC.
What key advantages does CTMC have in cell therapy development?
CTMC's strategic location and collaborative expertise allow for faster initiation of clinical trials and a clear path for commercialization.
How does CTMC ensure quality in its operations?
CTMC emphasizes a culture of quality assurance and continuous improvement, supported by Duane Avant’s extensive background and Lean Six Sigma certification.
